(0.34%) 5 109.00 points
(0.74%) 38 667 points
(0.60%) 17 756 points
(0.61%) $79.43
(0.88%) $2.05
(-0.10%) $2 307.20
(-0.54%) $26.69
(0.75%) $969.80
(-0.24%) $0.930
(-0.92%) $10.89
(-0.22%) $0.796
(0.62%) $91.69
@ $8.45
发出时间: 14 Feb 2024 @ 22:30
回报率: 10.89%
上一信号: Feb 14 - 02:42
上一信号:
回报率: 1.38 %
Live Chart Being Loaded With Signals
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia...
Stats | |
---|---|
今日成交量 | 455 277 |
平均成交量 | 403 190 |
市值 | 451.30M |
EPS | $0 ( 2024-02-26 ) |
下一个收益日期 | ( $-0.190 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.37 |
ATR14 | $0.0130 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Winningham Rick E | Buy | 300 000 | Ordinary Shares |
2024-04-02 | Sawaf Aziz | Buy | 100 000 | Ordinary Shares |
2024-04-02 | Miller Aine | Buy | 37 500 | Ordinary Shares |
2024-04-02 | Grimaud Brett A. | Buy | 100 000 | Ordinary Shares |
2024-04-02 | Farnum Rhonda | Buy | 37 500 | Ordinary Shares |
INSIDER POWER |
---|
47.04 |
Last 95 transactions |
Buy: 1 532 401 | Sell: 647 888 |
音量 相关性
Theravance Biopharma Inc 相关性 - 货币/商品
Theravance Biopharma Inc 财务报表
Annual | 2023 |
营收: | $57.42M |
毛利润: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2023 |
营收: | $57.42M |
毛利润: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2022 |
营收: | $51.35M |
毛利润: | $44.76M (87.17 %) |
EPS: | $-1.260 |
FY | 2021 |
营收: | $55.31M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。